Press Release Details

Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the appointment of Scott Chappel, Ph.D., as its Chief Scientific Officer (CSO). Reporting to Chief Executive Officer Michel Detheux, Ph.D., Dr. Chappel will be responsible for expanding the pipeline and leading the preclinical development of the Company’s best-in-class immuno-oncology programs that target the tumor microenvironment to improve the outcomes for cancer patients. 

“We are delighted that Scott has joined iTeos as CSO. He has been a leader in the life sciences sector for more than three decades and is an accomplished scientist who has directed research that has led to the development of several FDA-approved and marketed biological products,” commented Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “His experience will be invaluable to the next phase of our growth as we build an attractive pipeline and transition our programs into the clinic.”

With significant biotech experience and a strong scientific research and drug development track record, Dr. Chappel has founded and held several senior leadership roles in companies developing oncology and other novel therapies. Prior to joining iTeos, he was a founder and Chief Technology Officer at Surface Oncology, where he oversaw all antibody generation, engineering, production and characterization as well as all preclinical IND-enabling studies and GMP manufacturing of antibodies. He was also a founder and Chief Scientific Officer at Arteaus Therapeutics (acquired by Eli Lilly in 2014) and Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for the treatment of prostate cancer. Prior to Tokai, he held roles as a Senior Vice President of Research at Dyax and as a Chief Scientist at Serono. 

“I am thrilled to join iTeos as CSO and look forward to working with Michel and the team to rapidly advance the Company’s pipeline of high-value, immuno-oncology programs targeting the tumor microenvironment,” added Scott Chappel, Ph.D, Chief Scientific Officer of iTeos. “I am also very excited about the potential therapeutic benefits of EOS100850, an adenosine A_2A antagonist, and EOS884448, an anti-TIGIT antibody, which we expect to move into the clinic within 12 months.”

About iTeos Therapeutics 

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A_2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics

info@iteostherapeutics.com

Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

Sarah McCabe

Stern Investor Relations, Inc.

+ 1 212 362 1200

sarah@sternir.com